Ventripoint Joint Venture Begins Device Certification For Use In Covid Patients In China

Ventripoint Diagnostics (TSXV: VPT) is progressing with its joint venture partner in China. This morning the firm revealed that its partner, Yutian Medical Shanghai, has begun actively working with regulatory bodies to have its device certified for use with COVID patients.

The certification for this application follows Chinese guidelines being modified for the treatment and diagnosis of COVID-10 patients in the country, which now require monitoring of right-ventricular function by non-invasive techniques. Given the suitability of the QMS device (the rebranded name for VMS in the region) for such an application, the joint venture has begun the certification process.

To date, the venture has been successful in placing the devices in intensive care units, with further demand anticipated to meet potential future needs as the hospital deals with COVID. The application of the devices for this purpose as a result substantially expands the potential market for the device, beyond just that of cardiovascular disease.

Ventripoint Diagnostics last traded at $0.53 on the TSX Venture.


FULL DISCLOSURE: Ventripoint Diagnostics is a client of Canacom Group, the parent company of The Deep Dive. The company has been compensated to cover Ventripoint Diagnostics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Silver’s Finally Breaking the System | Keith Neumeyer – First Majestic

The Best News for Gold Was the Drop! – Peter Grandich

McEwen Copper: The Los Azules Feasibility Study

Recommended

Silver47 Completes Property-Wide Geochemical, Rock Sampling Program At Adams Plateau, Identifies Numerous Targets

Altamira Gold Identifies Presence Of Second Mineralized Porphyry Body At Cajueiro

Related News

George Adams: COVID-19 Damages The Heart – The Daily Dive

Today’s Daily Dive welcomes back Dr. George Adams, Executive Chairman of VentriPoint Diagnostics (TSXV: VPT)....

Friday, September 17, 2021, 01:30:00 PM

Ventripoint Installs First VMS+3.0 At Renowned US Cancer Hospital

Ventripoint Diagnostics (TSXV: VPT) this morning announced that it has installed its first VMS+3.0 whole-heart...

Thursday, October 8, 2020, 09:36:33 AM

Ventripoint Diagnostics: Using AI To Analyze The Heart – The Daily Dive feat George Adams

Today on the Daily Dive, our host Cassandra Leah sits down with George Adams, Executive...

Wednesday, April 21, 2021, 01:30:00 PM

Ventripoint Sees First Commercial Sales In China Through Joint Venture

Ventripoint Diagnostics (TSXV: VPT) this morning issued a brief press release related to its joint...

Tuesday, March 2, 2021, 08:25:53 AM

Ventripoint Looks To Raise $5.0 Million Via Bought Deal

Ventripoint Diagnostics (TSXV: VPT) this evening was halted for trading, ahead of announcing that the...

Tuesday, September 28, 2021, 07:33:00 AM